By Angela Leone
A new study authored by Dr. Lior Z. Braunstein, MD of Memorial Sloan Kettering Cancer Center and published in The Journal of the American Medical Association (JAMA) has confirmed a correlation between acid reflux treatment ranitidine (brand name ZANTAC) and the cancer causing substance N-nitrosodimethylamine, or NDMA.
The study created conditions in which ranitidine might yield NDMA by simulating gastric fluids (stomach acid) with varying levels of pH and nitrite. Ranitidine was then introduced to these conditions and detection methods were used to evaluate the presence of NDMA. Data analysis was conducted from June 1, 2019 through August 31, 2020 and found that ranitidine may be a significant source of cancer-causing NDMA under a “range of physiologically relevant conditions.”
Specifically, the study found that NDMA was produced at dangerous levels when ranitidine was introduced to simulations with lower pH, or more acidic conditions. The figure below shows the correlation between pH levels and NDMA formation. For context, the FDA has determined that safe daily consumption of NDMA for an adult is no more than .096 micrograms, or 96 nanograms, of NDMA.
Ranitidine is an acid reflux treatment intended to treat conditions like GERD, Zollinger-Ellison Syndrome, Dyspepsia, Hyperacidity, and other acid-related ailments. The results of Sloan Kettering’s study confirm that the very conditions that ranitidine was distributed to treat are the conditions that make ranitidine so dangerous.
If you or a loved one have been diagnosed with cancer after a year or more of Zantac(ranitidine) use, please contact our office for a free case evaluation. Over the last year, our Zantac legal team has spoken with hundreds of claimants just like you, helping them get registered within the ongoing litigation and keeping them updated about the status of their case. Call us at 877-637-7252, or fill out the preliminary documents online at messalaw.com/zantac.